Item 2.02 Results of Operations and Financial Condition.

On January 11, 2021, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release (the "Press Release") announcing preliminary unaudited fiscal year 2020 revenue for Crysvita® in the Company's territories, cash and investments at 2020 fiscal year end and 2021 revenue guidance for Crysvita® in the Company's territories. The Company expects to report its full year results for the 2020 fiscal year in February 2021. A copy of the Press Release is furnished herewith as Exhibit 99.1.

The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 11, 2021, the Company posted a presentation (the "Presentation") to its website at www.ultragenyx.com in the "Events and Presentations" subsection of the "Investors" tab. The Company is scheduled to present the Presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021.

The information set forth under Item 7.01 and in the Presentation shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated January 11, 2021.
104         The cover page from the Company's Current Report on Form 8-K dated
            January 11, 2021 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses